• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Acrivon Therapeutics Inc.

    7/10/24 8:34:52 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRV alert in real time by email
    SC 13G/A 1 ea0208963-13ga2chione_acri.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Acrivon Therapeutics, Inc.
    (Name of Issuer)

     

    Common Stock
    (Title of Class of Securities)

     

    004890109
    (CUSIP Number)

     

    June 30, 2024
    (Date of Event Which Requires Filing of this Statement)

       

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 004890109  

     

    1.

    NAMES OF REPORTING PERSONS

    Chione Limited

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

    (a)    ☐

    (b)    ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    CYPRUS  

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,848,632

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,848,632

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,848,632

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    12.5%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    CO

     

    2

     

     

    CUSIP No. 004890109        

     

    1.

    NAMES OF REPORTING PERSONS

    Marcin Czernik

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

    (a)    ☐

    (b)    ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    POLAND

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,848,632

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,848,632

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,848,632

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    12.5%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN, HC

     

    3

     

     

    CUSIP No. 004890109        

     

    1.

    NAMES OF REPORTING PERSONS

    Andreas Hadjimichael

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

    (a)    ☐

    (b)    ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    CYPRUS

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,848,632

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,848,632

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,848,632

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    12.5%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN, HC

     

    4

     

     

    CUSIP No. 004890109        

     

    1.

    NAMES OF REPORTING PERSONS

    Anastasis Nikolaou

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

    (a)    ☐

    (b)    ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    CYPRUS

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,848,632

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,848,632

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,848,632

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    12.5%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN, HC

     

    5

     

     

    CUSIP No. 004890109        

     

    1.

    NAMES OF REPORTING PERSONS

    Wiaczeslaw Smolokowski

     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

    (a)    ☐

    (b)    ☐

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    CYPRUS

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    3,848,632

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    3,848,632

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,848,632

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    12.5%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN, HC

     

    6

     

     

    ITEM 1(A) NAME OF ISSUER: Acrivon Therapeutics, Inc.

     

    ITEM 1(B) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: 480 Arsenal Way, Suite 100, Watertown, Massachusetts

     

    ITEM 2 (A) NAME OF PERSON FILING: This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    (i)Chione Limited. (“Chione”)

     

    (ii)Marcin Czernik

     

    (iii)Andreas Hadjimichael

     

    (iv)Anastasis Nikolaou

     

    (v)Wiaczeslaw Smolokowski

     

    ITEM 2 (B) ADDRESS OR PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The principal business office of each of the Reporting Persons (other than Mr. Smolokowski) is Simou Menardou 5, Kifisia Court. Office 225, 6015 Larnaca, Cyprus. The residence address of Mr. Smolokowski is Chalet Lenotchka, Chemin des Marais 1, Chesieres, Switzerland.

     

    ITEM 2 (C) CITIZENSHIP (i) Chione is a Cyprus corporation.

     

    (ii)Messrs. Hadjimichael and Nikolaou are citizens of the Republic of Cyprus.

     

    (iii)Messrs. Czernik and Smolokowski are citizens of the Republic of Poland.

     

    ITEM 2 (D) TITLE OF CLASS OF SECURITIES: Common Stock, par value $0.001 per share (the “Common Stock”), of Acrivon Therapeutics, Inc., a Delaware corporation (the “Issuer”)

     

    ITEM 2 (E) CUSIP NO.: 004890109

     

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    7

     

     

    ITEM 4. OWNERSHIP 

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The percentages set forth herein are calculated based upon 30,876,932 shares of Common Stock outstanding, as of May 9, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ending March 31, 2024 filed with the Securities and Exchange Commission on May 14, 2024. These shares of Common Stock are owned directly by Chione. Chione’s directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole stockholder, Wiaczeslaw Smolokowski, may be deemed to share voting and investment power and beneficial ownership of such shares of Common Stock. Each of such directors and stockholder disclaims such voting and investment power and beneficial ownership.

     

    ITEM 5. OWNERSHIP OF 5 PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    ITEM 6. OWNERSHIP OF MORE THAN 5 PERCENT ON BEHALF OF ANOTHER PERSON. Not applicable.

     

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON.

     

    Not applicable.

     

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable.

     

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Not applicable.

     

    ITEM 10. CERTIFICATIONS

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      July 10, 2024
      Date
       
      Chione Limited, by /s/ Shalom Leaf, as attorney-in-fact
    Marcin Czernik, by /s/ Shalom Leaf, as attorney-in-fact
    Andreas Hadjimichael, by /s/ Shalom Leaf, as attorney-in-fact
    Anastasis Nikolaou, by /s/ Shalom Leaf, as attorney-in-fact
    Wiaczeslaw Smolokowski, by /s/ Shalom Leaf, as attorney-in-fact

     

    Exhibit Index

     

    Exhibit 24.1 –   Power of Attorney, dated May 15, 2024, made by Marcin Czernik and Chione Limited in favor of Shalom Leaf (incorporated by reference to Exhibit 24.1 to the Form 13G/A (Amendment No. 1), filed on behalf of Chione Limited et al on 7/10/24)
    Exhibit 24.2 –   Power of Attorney, dated May 15, 2024, made by Andreas Hadjimichael and Chione Limited in favor of Shalom Leaf (incorporated by reference to Exhibit 24.2 to the Form 13G/A (Amendment No. 1), filed on behalf of Chione Limited et al on 7/10/24)
    Exhibit 24.3 –   Power of Attorney, dated May 15, 2024, made by Wiaczeslaw Smolokowski in favor of Shalom Leaf  (incorporated by reference to Exhibit 24.3 to the Form 13G/A (Amendment No. 1), filed on behalf of Chione Limited et al on 7/10/24)
    Exhibit 24.4 –   Power of Attorney, dated May 15, 2024, made by Anastasis Nikolaou and Chione Limited in favor of Shalom Leaf (incorporated by reference to Exhibit 24.4 to the Form 13G/A (Amendment No. 1), filed on behalf of Chione Limited et al on 7/10/24)
    Exhibit 99.1 –   Joint Filing Agreement, dated July 10, 2024, among the Reporting Persons

     

     

    9

     

    Get the next $ACRV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRV

    DatePrice TargetRatingAnalyst
    5/5/2025$6.00Overweight
    Piper Sandler
    1/31/2025Overweight
    KeyBanc Capital Markets
    9/16/2024$16.00Neutral → Buy
    Ladenburg Thalmann
    4/29/2024Buy → Neutral
    Ladenburg Thalmann
    3/1/2024$14.00Mkt Outperform
    JMP Securities
    12/15/2023$17.00 → $12.00Buy
    Jefferies
    10/5/2023Buy
    Maxim Group
    6/2/2023$25.00Outperform
    Oppenheimer
    More analyst ratings

    $ACRV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Acrivon Therapeutics with a new price target

    Piper Sandler resumed coverage of Acrivon Therapeutics with a rating of Overweight and set a new price target of $6.00

    5/5/25 8:30:14 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Acrivon Therapeutics

    KeyBanc Capital Markets initiated coverage of Acrivon Therapeutics with a rating of Overweight

    1/31/25 8:29:16 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Acrivon Therapeutics from Neutral to Buy and set a new price target of $16.00

    9/16/24 7:17:32 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

    Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized solid tumor types Expanding power of Generative Phosphoproteomics AP3 supersedes conventional target-centric drug discovery, yielding differentiated compounds with desired pathway effects Cash, cash equivalents and marketable securities of $134.4 million as of September 30, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a

    11/13/25 4:10:00 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

    AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development Favorable ACR-2316 preclinical data, demonstrating its differentiated and superior pathway effects versus benchmark WEE1 and PKMYT1 inhibitors consistent with prior observations Company to report initial clinical data for ACR-2316 in AP3-predicted tumor types later this year; clinical activity and confirmed partial response observed during dose escalation  WATERTOWN, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology

    10/22/25 4:15:41 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of October 1, 2025. Th

    10/1/25 4:30:00 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Perceptive Advisors Llc bought $20,000,500 worth of shares (2,353,000 units at $8.50) (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    4/15/24 8:53:49 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Blume-Jensen Peter covered exercise/tax liability with 19,904 shares (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    11/25/25 4:03:56 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Peterson Katharine covered exercise/tax liability with 99 shares, decreasing direct ownership by 2% to 4,122 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    11/18/25 4:33:56 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Miller Mary covered exercise/tax liability with 184 shares, decreasing direct ownership by 0.53% to 34,555 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    11/18/25 4:32:18 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Acrivon Therapeutics Inc.

    SCHEDULE 13G - Acrivon Therapeutics, Inc. (0001781174) (Subject)

    11/21/25 5:36:58 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Acrivon Therapeutics Inc.

    SCHEDULE 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

    11/14/25 4:07:17 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Acrivon Therapeutics Inc.

    10-Q - Acrivon Therapeutics, Inc. (0001781174) (Filer)

    11/13/25 4:17:24 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Leadership Updates

    Live Leadership Updates

    View All

    Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

    Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types WATERTOWN, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage precision medicine company utilizing its Acriv

    4/7/25 4:05:00 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

    WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided business highlights. "On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year

    3/28/24 8:00:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

    WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors. "Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precisi

    3/4/24 8:00:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Acrivon Therapeutics Inc.

    SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

    7/10/24 8:34:52 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acrivon Therapeutics Inc.

    SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

    7/10/24 8:29:53 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Acrivon Therapeutics Inc. (Amendment)

    SC 13G/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)

    4/15/24 8:21:55 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care